Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma

Pediatric Blood and Cancer

Volumn 60, Issue 4, 2013, Pages 593-598

  Rednam, Surya ^a   Scheurer, Michael E ^a   Adesina, Adekunle ^a   Lau, Ching C ^a   Okcu, Mehmet Fatih ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Glutathione S transferase; Medulloblastoma; Ototoxicity; Polymorphism; Radiation

Indexed keywords

AMIFOSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; GLUTATHIONE TRANSFERASE P1; REACTIVE OXYGEN METABOLITE; VINCRISTINE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; DRUG SAFETY; FEMALE; FOLLOW UP; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEARING AID; HEARING IMPAIRMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIMODALITY CANCER THERAPY; NEUROECTODERM TUMOR; OTOTOXICITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HEARING LOSS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIOTHERAPY;

EID: 84873736779     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24366     Document Type: Article

References (36)

1. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology, 6th edition. Philadelphia: Lippincott Williams & Wilkins; 2011. pp 772-782.
2. McNeil DE, Cote TR, Clegg L, et al. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update. Surveillance epidemiology and end results. Med Pediatr Oncol 2002; 39: 190-194.
3. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St. Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 7: 813-820.
4. Packer RJ, Gajjar A, Vezina G, et al. Phase III Study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24: 4202-4208.
5. Pomeroy SL. Epidemiology, treatment, and prognosis of medulloblastoma. UpToDate. http://www.uptodate.com/contents/epidemiology-treatment-and-prognosis-of-medulloblastoma. Accessed October 21, 2011.
6. Hoffman KE, Yock TI. Radiation therapy for pediatric central nervous system tumors. J Child Neurol 2009; 24: 1387-1396.
7. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29: 1408-1414.
8. Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29: 1424-1430.
9. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: Cancer incidence and therapy. Oncogene 2006; 25: 1639-1648.
10. Kilburn L, Okcu MF, Wang T, et al. Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. Cancer 2010; 116: 2242-2249.
11. Okcu MF, Selvan M, Wang LE, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 2004; 10: 2618-2625.
12. Armstrong TS, Cao Y, Scheurer ME, et al. Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors. Neuro Oncol 2009; 11: 825-832.
13. Zielinska E, Zubowska M, Misiura K. Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. J Pediatr Hematol Oncol 2005; 27: 582-589.
14. Lo HW, Ali-Osman F. Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr Opin Pharmacol 2007; 7: 367-374.
15. Zschenker O, Raabe A, Boeckelmann IK, et al. Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity. Radiother Oncol 2010; 97: 26-32.
16. Ali-Osman F, Brunner JM, Kutluk TM, et al. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 1997; 3: 2253-2261.
17. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005; 11: 2215-2221.
18. Surowiak P, Materna V, Kaplenko I, et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavorable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 2005; 447: 626-633.
19. Tabuchi K, Nishimura B, Nakamagoe M, et al. Ototoxicity: Mechanisms of cochlear impairment and its prevention. Curr Med Chem 2011; 18: 4866-4871.
20. Low WK, Tan MG, Chua AW, et al. 12th Yahya Cohen Memorial Lecture: The cellular and molecular basis of radiation-induced sensori-neural hearing loss. Ann Acad Med Singapore 2009; 38: 91-94.
21. Jereczek-Fossa BA, Zarowski A, Milani F, et al. Radiotherapy-induced ear toxicity. Cancer Treat Rev 2003; 29: 417-430.
22. Barahmani N, Carpentieri S, Li XN, et al. Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma. Neuro Oncol 2009; 11: 292-300.
23. Oldenburg J, Kraggerud SM, Cvancarova M, et al. Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007; 25: 708-714.
24. Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000; 11: 639-643.
25. Ross CJ, Katzov-Eckert H, Dube MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41: 1345-1349.
26. Ambrosone CB, Tian C, Ahn J, et al. Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: A case-series study. Breast Cancer Res 2006; 8: R40.
27. Edvardsen H, Kristensen VN, Grenaker Alnaes GI, et al. Germline glutathione S-transferase variants in breast cancer: Relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67: 1163-1171.
28. Yoon HH, Catalano P, Gibson MK, et al. Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: Results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol 2011; 68: 863-870.
29. Ishimoto TM, Ali-Osman F. Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli. Pharmacogenetics 2002; 12: 543-553.
30. Peklak-Scott C, Smitherman PK, Townsend AJ, et al. Role of glutathione S-transferase P 1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 2008; 7: 3247-3255.
31. Bravard A, Luccioni C, Moustacchi E, et al. Contribution of antioxidant enzymes to the adaptive response to ionizing radiation of human lymphoblasts. Int J Radiat Biol 1999; 75: 639-645.
32. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649-655.
33. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer 2004; 40: 2445-2451.
34. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23: 8588-8596.
35. Paulino AC, Lobo M, Teh BS, et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys 2010; 78: 1445-1450.
36. Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 2008; 26: 3749-3755.